Lilly, Bristol Drug Dilution Settlement May Increase Focus On “Gray Market”
Executive Summary
The size of settlement payments made by Lilly and Bristol-Myers Squibb in the Kansas City drug dilution case is the latest warning to manufacturers that they may need to become more aggressive in policing the so-called "gray market" for pharmaceuticals
You may also be interested in...
GSK Selling Direct To Canadian Pharmacies, Auditing Orders To Curb Imports
GlaxoSmithKline is selling its products direct to pharmacies in Canada that are suspected by the company of selling to consumers in the U.S
Lilly Finds IMS Data Solution, Uncovers Gemzar Dilution In Kansas City
Lilly's decision to use IMS Health's wholesale tracking data in the Kansas City area for oncology sales rep bonuses helped lead to the discovery that an area pharmacist appeared to be diluting chemotherapy drugs.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011